Infecciones por el virus de Epstein-Barr y citomegalovirus

  1. Tinoco Racero, I.
  2. Caro Gómez, N.
  3. Rodríguez Leal, M. C.
  4. López Tinoco, Elena
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2014

Título do exemplar: Enfermedades infecciosas (II): infecciones víricas

Serie: 11

Número: 50

Páxinas: 2954-2964

Tipo: Artigo

DOI: 10.1016/S0304-5412(14)70722-X DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Infections by Epstein-Barr virus is the most common cause of infectious mononucleosis. We describe the diagnosis and different serological patterns, as well as its major complications related to the development of malignancies, lymphoproliferative disorders and autoimmune diseases. There is no effective treatment. Cytomegalovirus is the second cause of mononucleosis syndrome and the first of congenital infection in our environment. It has an high morbidity and mortality in immunocompromised patients, mainly solid organ transplants, bone marrow and coinfection by human immunodeficiency virus. Its treatment is based on antivirals, mainly ganciclovir and valganciclovir. We describe its management, adverse effects, new drugs and prophylaxis.

Referencias bibliográficas

  • Adler SP. Immunization to prevent congenital cytomegalovirus infection. Br Med . 2013;107:57-68.
  • Aguado JM, Navarro D, San Juan R, Castón JJ. Cytomegalovirus infection in solid organ transplantation. Enferm Infecc Microbiol Clin. 2012;30Suppl2:57-62.
  • Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a minireview. Cancer Lett. 2014;342(1):1-8.
  • Avery RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12:489-96.
  • Benoist G, Leruez-Ville M, Magny JF, Jacquemard F, Salomon LJ, Ville Y. Management of pregnancies with confirmed cytomegalovirus fetal infec-tion. Fetal Diagn Ther. 2013;33:203-14.
  • Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117:53-62.
  • Chovel-Sella A, Ben Tov A, Lahav E, Mor O, Rudich H, Paret G. Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics. 2013;131:e1424-7.
  • Crawford DH, Macsween KF, Higgins CD, Thomas R, McAulay K, Williams H. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis. 2006;43:276-82.
  • Crumpacker CS II, Zhang JL. Cytomegalovirus. Mandell, Douglas and Bennett ́s Principle and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2010. p. 1971-87.
  • De la Torre-Cisneros J, Fariñas MC, Castón JJ, Aguado JM, Cantisán S, Carratalá J. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin. 2011;29 735-58.
  • Dunleavy K, Roschewski M, Wilson WH. Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes. Curr Hematol Malig Rep. 2012;7:208-15.
  • Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician. 2004;70:1279-87.
  • Enders G, Daiminger A, Bäder U, Exler S, Schimpf Y, Enders M. The value of CMV IgG avidity and immunoblot for timing the onset of primary CMV infection in pregnancy. J Clin Virol. 2013;56:102-7.
  • Epstein Barr virus, including infectious mononucleosis. Harrison ́s Principles of Internal Medicine. 18th ed. USA: McGraw-Hill; 2012.
  • Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus related disease. J Mol Diagn. 2008;10:279-92.
  • Härter G, Michel D. Antiviral treatment of cytomegalovirus infection: an update. Expert Opin Pharmacother. 2012;13:6237.
  • Hodson E, Barclay P, Craig J, Jones C, Kable K, Strippoli G. Antiviral medication for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2007;(2):CD005129.
  • Hussain RS, Hussain NA. Ataxia and encephalitis in a young adult with EBV mononucleosis: a case report. Case Rep Neurol Med. 2013. Dis-ponible en: dx.doi.org/10.1155/2013/516325.
  • Jain M, Duggal S, Chugh TD. Cytomegalovirus infection in non immunosuppressed critically ill patients. J Infect Dev Ctries. 2011;5:571-9.
  • Johannsen EC, Kaye KM. Epstein-Barr (infectious mononucleosis, Epstein-Barr virus associated malignant diseases, and other diseases). Mandell, Douglas and Bennett ́s Principle and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2010. p. 1989-2010.
  • Klemola E, Von Essen R, Henle G, Henle W. Infectious mononucleosis like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis. 1970;121:608-14.
  • Lossius A, Johansen JN, Torkildsen Ø, Vartdal F, Holmøy T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis: association and causation. Viruses. 2012;4:3701-30.
  • Lunn M, Hughes R. The relationship between cytomegalovirus infection and Guillain–Barré syndrome. Clin Infect Dis. 2011;52: 845-7.
  • Luzuriaga K, Sullivan JL. Infectious mononucleosis. N Engl J Med. 2010;362:1993-2000.
  • Maakaroun NR, Moanna A, Jacob JT, Albrecht H. Viral infections associ-ated with haemophagocytic syndrome. Rev Med Virol 2010; 20: 93-105.
  • Macsween KF, Higgins CD, McAulay KA, Williams H, Harrison N, Swerdlow AJ. Infectious mononucleosis in university students in the United kingdom: evaluation of the clinical features and consequences of the disease. Clin Infect Dis. 2010;50:699-706.
  • Moormann AM, Snider CJ, Chelimo K. The company malaria keeps: how coinfection with Epstein-Barr virus leads to endemic Burkitt lymphoma. Curr Opin Infect Dis. 2011;24:435-41.
  • Morris MC, Edmunds WJ. The changing epidemiology of infectious mononucleosis? J Infect. 2002;45:107-9.
  • Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13: R68.
  • Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49:151-7.
  • Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a sys-tematic review. Virol J. 2008;5: 47.
  • Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost. 2011;106:858-67.
  • Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets. 2011;11:466-74.
  • Santos Luna F, Carratalà J. Tratamiento de la enfermedad por citomegalovirus. Enferm Infecc Microbiol Clin. 2011;29Suppl6:65-9.
  • Takeuchi K, Tanaka-Taya K, Kazuyama Y, Ito YM, Hashimoto S, Fukayama M. Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol Int. 2006;56:112-6.
  • Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res. 2004;10:803-21.
  • Thorley-Lawson DA, Gross A. Persistence of the Epstein–Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350:1328-37.
  • Tomtishen JP 3rd. Human cytomegalovirus tegument proteins (pp65, pp71, pp150, pp28). Virol J. 2012;9:22. Vouloumanou EK, Rafailidis PI, Falagas ME. Current diagnosis and management of infectious mononucleosis. Curr Opin Hematol. 2012;19:14-20.
  • Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041-54.
Fonte de datos: Dialnet